New Study Reveals Unexpected Way To Destroy Pancreatic Cancer Cells
A breakthrough study has uncovered a surprising strategy to fight pancreatic cancer, one of the deadliest and hardest‑to‑treat cancers. Instead of shutting down growth signals, researchers found that overstimulating key pathways may push cancer cells into self‑destruction.
Turning Growth Against Cancer
The research, published in Aging by scientists at Florida A&M University, focused on pancreatic ductal adenocarcinoma, a cancer often driven by KRAS mutations. KRAS acts like a stuck accelerator, forcing cells to grow and spread uncontrollably. Researchers tested PCAI compounds designed to disrupt abnormal KRAS activity. Two compounds NSL‑YHJ‑2‑45 and NSL‑YHJ‑2‑27 proved especially effective. At low doses, they reduced cancer cell survival and sharply limited mobility. NSL‑YHJ‑2‑27 blocked more than 90% of cell migration at just 1 μM, preventing cancer cells from spreading. Treated cells became rounder, lost their extensions, and showed signs of apoptosis, or controlled cell death.
Overdrive Strategy
Unexpectedly, the compound didn’t simply silence KRAS signals. Instead, it pushed growth pathways into overdrive, creating internal stress. This triggered a surge in reactive oxygen species, damaging the cells and accelerating their death. In 3D tumor spheroids structures that mimic real tumors PCAIs caused clusters to break apart and reduced invasion by up to 96%. Gene activity also shifted: tumor‑suppressing genes became more active, while cancer‑promoting genes were reduced.
Unlike current KRAS drugs that target only one mutation (KRAS G12C), PCAIs showed promise across multiple mutations, including KRAS G12D. This suggests potential for wider use in pancreatic and other KRAS‑driven cancers.
Though still in early stages, PCAIs highlight a bold new approach: turning cancer’s own growth signals into a liability. If future studies confirm safety and effectiveness, this strategy could open new doors for treating pancreatic cancer.
